Weekly Digest – November 2024 Weekly Digest – November 2024 07 Nov 2024: AstraZeneca to build Antibody Drug Conjugate (ADC) manufacturing facility in Singapore AstraZeneca held a groundbreaking ceremony on November 7 for its new Antibody Drug Conjugate (ADC) Manufacturing […]
Weekly Digest – November 2024 Weekly Digest – November 2024 07 Nov 2024: ADC Therapeutics axes lead solid tumor drug after phase 1 setback, pivots to preclinical programs ADC Therapeutics has stopped the development of its lead solid tumor candidate, […]
Weekly Digest – November 2024 Weekly Digest – November 2024 06 Nov 2024: NextCure reports preclinical data for LNCB74 and additional clinical biomarker data for NC410 combo at Society for Immunotherapy of Cancer Annual Meeting NextCure announced preclinical data for […]
Weekly Digest – November 2024 Weekly Digest – November 2024 06 Nov 2024: Celltrion unveils development of two cancer drugs Celltrion unveiled two new ADC candidates, CT-P70 and CT-P71, at the World ADC 2024 conference, marking its first public disclosure […]
Weekly Digest – November 2024 Weekly Digest – November 2024 06 Nov 2024: MacroGenics pauses work on vobra duo ADC pending mature survival data MacroGenics has paused investment in vobra duo and related studies pending updated data from the Phase […]
Weekly Digest – October 2024 Weekly Digest – October 2024 24 Oct 2024: ABL Bio introduces platform tech to speed up developing bispecific ADCs ABL Bio has signed a technology transfer agreement with IntoCell, which specializes in ADC technology, to […]
Weekly Digest – October 2024 Weekly Digest – October 2024 24 Oct 2024: As DLL3 heats up, early data for Zai Lab’s ADC sets up case for differentiation Zai Lab is positioning its DLL3-targeting ADC ZL-1310 in the extensive-stage small-cell […]
Weekly Digest – October 2024 Weekly Digest – October 2024 23 Oct 2024: Hengrui initiated the phase II clinical study of nectin-4 ADC monotherapy for advanced gynecological tumors Hengrui has initiated a Phase II clinical study of SHR-A2102, an ADC […]
Weekly Digest – October 2024 Weekly Digest – October 2024 21 Oct 2024: Adcentrx Therapeutics announces FDA clearance of Investigational New Drug Application for ADRX-0405, a potential first-in-class ADC targeting STEAP1 for the treatment of advanced solid tumors Adcentrx Therapeutics […]
Weekly Digest – October 2024 Weekly Digest – October 2024 18 Oct 2024: Gilead pulls Trodelvy’s approval in bladder cancer after trial flop, FDA discussions Gilead Sciences has announced the withdrawal of Trodelvy as a treatment for bladder cancer in […]
